Burzynski Research Institute Inc BZYR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.04
- Day Range
- $0.03–0.04
- 52-Week Range
- $0.01–0.09
- Bid/Ask
- $0.03 / $0.06
- Market Cap
- $5.62 Mil
- Volume/Avg
- 2,425 / 11,679
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Burzynski Research Institute Inc engages in the research, production, marketing, promotion, and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are used in the treatment of human cancer. Its pipeline development programs of the company include clinical trials for the treatment of a wide variety of cancers using only a combination of Antineoplastons A10 and AS2-1.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- http://www.burzynskiresearch.com
Valuation
|
Metric
|
BZYR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BZYR
|
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.03 |
Interest Coverage | — |
Quick Ratio
BZYR
Profitability
|
Metric
|
BZYR
|
|---|---|
Return on Assets (Normalized) | −80,479.55% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BZYR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lklkgcksnf | Lqsy | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ctvnylmp | Bqhvvlh | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mrzwcyq | Nrcpk | $97.8 Bil | |
MRNA
| Moderna Inc | Zjzkpgy | Prxl | $38.8 Bil | |
ARGX
| argenx SE ADR | Vghxygpjh | Jdwxx | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Wmmcwpk | Stdgx | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bsvjvhqtr | Vjzjv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qkwnnbc | Svhgc | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lzbrnyhcf | Cszqbt | $12.5 Bil | |
INCY
| Incyte Corp | Zgvbrnvcp | Zcnynyd | $11.6 Bil |